Can PSA levels measured at 6, 12, and 24 weeks predict my long-term survival?
For men with prostate cancer, especially those receiving hormone therapy (androgen deprivation therapy or ADT), doctors often track PSA levels over time. A large study from the STAMPEDE trial found that PSA levels measured at 6, 12, and 24 weeks after starting treatment were linked to overall survival at 96 months (8 years). Lower PSA levels at these time points were associated with better long-term survival. This means that early PSA changes can give you and your doctor important clues about how well your treatment is working and what your outlook may be.
What the research says
A major analysis from the STAMPEDE platform trial looked at PSA levels in men with metastatic or very high-risk non-metastatic prostate cancer who were starting hormone therapy. Researchers measured PSA at 6, 12, and 24 weeks after randomization and then tracked survival for up to 96 months. They found that lower PSA levels at each of these early time points were significantly linked to longer overall survival 3. This suggests that how quickly and how much PSA drops in the first few months of treatment can serve as an early marker of treatment effectiveness and long-term prognosis.
Another study examined PSA kinetics (how PSA changes over time) in men receiving 6 months of hormone therapy before radiation. It found that a longer PSA halving time (meaning PSA drops more slowly) was linked to worse outcomes. Testosterone escape (when testosterone levels rise despite treatment) also slowed PSA decline 10. This reinforces that early PSA patterns matter.
It is important to note that PSA is not the only factor. Other tools, such as artificial intelligence models, are being studied to predict prostate cancer outcomes, including overall survival 4. However, the STAMPEDE data provide strong, direct evidence that early PSA measurements at 6, 12, and 24 weeks are useful predictors of long-term survival in men starting hormone therapy for advanced prostate cancer.
What to ask your doctor
- What do my PSA levels at 6, 12, and 24 weeks after starting treatment suggest about my long-term outlook?
- How does my PSA nadir (lowest level) compare to typical targets for my type of prostate cancer?
- If my PSA is not dropping as expected, what other treatment options might we consider?
- Should I have additional tests, such as imaging or genetic testing, to better predict my prognosis?
- How often should we monitor my PSA after the first 24 weeks to track my response?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.